NEWCELX AG

NewcelX is selling 347,134 common shares plus warrants over an additional 347,134 shares at a price of 4.033 USD per share, representing a 20% premium to the closing price; the exercise price of the warrants is 4.437 USD. Both existing and new investors are participating in the private placement, with closing expected on August 14, 2026, subject to customary conditions. The net proceeds, together with available cash and an already announced 25 million USD equity financing facility, are intended to fund further development of NCEL-101 for the treatment of type 1 diabetes, working capital and general corporate purposes. » Więcej na de.investing.com

NewcelX has appointed Dr. med. Camillo Ricordi to its scientific advisory board; the appointment follows a Type-B pre-IND meeting with the FDA regarding its lead program NCEL-101. Ricordi brings extensive experience in cell transplantation and regenerative medicine and is expected to support the clinical strategy and collaboration with Eledon Pharmaceuticals. NewcelX is a clinically focused biotech company for type 1 diabetes; the stock last traded at 4.01 USD and has risen 81% over six months. » Więcej na de.investing.com

NewcelX completed a pre‑IND Type B meeting with the FDA and received feedback on CMC processes and the preclinical program for NCEL‑101. The feedback enables preparation of an IND filing for a clinical trial in which NCEL‑101 is to be combined with Tegoprubart. NCEL‑101 is a stem‑cell‑based islet cell candidate intended to preserve graft function without calcineurin inhibitors; the company now sees a clearly defined clinical path. » Więcej na de.investing.com